Advertisement

Flow Features of Immunoglobulin A Nephropathy Depending on Activity / Risk of Progression and Influence of Pathogenetic Therapy

  • Olga Nikolaevna SigitovaEmail author
  • Taisia Yurevna Kim
  • Alexandra Vladimirovna Salmakova
Article
  • 1 Downloads

Abstract

Optimization of the choice of the treatment method, improving the prognosis of the immunoglobulin A nephropathy (IgAN). Seventy-six patients with morphologically confirmed IgAN from 21 to 73 years old (33.9 ± 1.2 years old, M/F = 47/29). There were analyzed the rates of progression of nephritis in these patients with a natural course of the disease and induced treatment, with a duration of nephropathy at 1 to 27 years (9.6 ± 0.9) in three groups with a different degree of activity of nephropathy. The natural rates of progression of IgA nephropathy are determined by its activity; the rate of progression of nephropathy increases with the increasing proteinuria (PU) and the greatest in patients with nephrotic proteinuria. Carrying out pathogenetic therapy, the choice which is determined by the activity of nephropathy helps to reduce the PU and slow the progression. In most patients, IgAN had a recurrent course. The frequency of relapses of IgAN did not depend on the pathogenetic therapy.

Keywords

IgA nephropathy Treatment Nephroprotection The frequency of relapses Rates of progression 

Notes

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest. Authors are solely responsible for submitting the final manuscript to print.

The work was performed according to the Russian Government Program of Competitive Growth of Kazan Federal University and subsidy allocated to Kazan Federal University for the state assignment in the sphere of scientific activities.

References

  1. 1.
    Картамышева Н.Н., Чумакова О.В., Кучеренко А.Г. и др. (2003). Прогрессирование хронического гломерулонефрита: клинико-морфологические взаимосвязи. Нефрология и диализ; 5 (4): 395–398. [Kartamysheva N.N., Chumakova O.V., Kucherenko A.G. et al. Progression of chronic glomerulonephritis: correlations of clinical and morphological peculiarities. Nefrologiya i dializ. 2003; 5 (4): 395–398. (In Russ.)].Google Scholar
  2. 2.
    Hotta, O., Miyazaki, M., Furuta, T., et al. (2001). Tonsillectomy and steroid pulse therapy significantly impact on clinical remission in patients with IgA nephropathy. American Journal of Kidney Diseases, 38(4), 736–743.  https://doi.org/10.1053/ajkd.2001.27690.CrossRefGoogle Scholar
  3. 3.
    Шилов Е.М., Тареева И.Е., Иванов А.А. (2002) и др. Течение и прогноз мезангиопролиферативного гломерулонефрита. Тер.арх.; 74 (6): 11–18. [Shilov E.M., Tareeva I.E., Ivanov A.A. et al. The course and prognosis of mesangial proliferative glomerulonephritis. Terapevticheskiy arkhiv. 2002; 74 (6): 11–18. (In Russ.)]Google Scholar
  4. 4.
    Sobarzo Toro, M., & Vilches, A. (2004). Membranous kidney diseases in adults. Medicina (B Aires)., 64(1), 59–65.Google Scholar
  5. 5.
    Шилов Е.М., Иванов A.A., Троепольская О.В., Краснова Т.Н. (2001). Течение и прогноз мезангиопролиферативного гломерулонефрита. Успехи нефрологии: сб. науч. тр.М.: ММА им. Сеченова; 165–183. [Shilov E.M., Ivanov A.A., Troepol’skaya O.V., Krasnova T.N. Techenie i prognoz mezangioproliferativnogo glomerulonefrita. Uspekhi nefrologii: sbornik nauchnykh trudov. (The course and prognosis of mesangial proliferative glomerulonephritis. The successes of nephrology: a collection of scientific papers.) Moscow: MMA im. Sechenova. 2001; 165–183. (In Russ.)].Google Scholar
  6. 6.
    D’Amico, G. (2000). Natural history of idiopathic IgA nephropathy: role of clinical and histological prognostic factors. American Journal of Kidney Diseases, 36(2), 227–237.  https://doi.org/10.1053/ajkd.2000.8966.MathSciNetCrossRefGoogle Scholar
  7. 7.
    Szeto, C. C., Lai, F. M., To K.F, et al. (2001). The natural history of immunoglobulin a nephropathy among patients with hematuria and minimal proteinuria. The American Journal of Medicine, 110(6), 434–437.  https://doi.org/10.1016/S0002-9343(01)00659-3.CrossRefGoogle Scholar
  8. 8.
    Barbour, S. J., & Reich, H. N. (2012). Risk stratification of patients with IgA nephropathy. American Journal of Kidney Diseases, 59(6), 865–873.  https://doi.org/10.1053/j.ajkd.2012.02.326.CrossRefGoogle Scholar
  9. 9.
    Beck, L., Bomback, A. S., Choi, M. J., et al. (2013). KDOQI US commentary on the 2012 KDIGO clinical practice guideline for glomerulonephritis. American Journal of Kidney Diseases, 62(3), 403–441.  https://doi.org/10.1053/j.ajkd.2013.06.002.CrossRefGoogle Scholar
  10. 10.
    Bartosik, L. P., Lajoie, G., Sugar, L., & Cattran, D. C. (2001). Predicting progression in IgA nephropathy. American Journal of Kidney Diseases, 38(4), 728–735.  https://doi.org/10.1053/ajkd.2001.27689.CrossRefGoogle Scholar
  11. 11.
    Le, W., Liang, S., Hu, Y., et al. (2012). Long-term renal survival and related risk factors in patients with IgA nephropathy: results from a cohort of 1155 cases in a Chinese adult population. Nephrology, Dialysis, Transplantation, 27(4), 1479–1485.  https://doi.org/10.1093/ndt/gfr527.CrossRefGoogle Scholar
  12. 12.
    Gutierrez, E., Zamora, I., Ballarin, J. A., et al. (2012). Long-term outcomes of IgA nephropathy presenting with minimal or no proteinuria. Journal of the American Society of Nephrology, 23(10), 1753–1760.  https://doi.org/10.1681/ASN.2012010063.CrossRefGoogle Scholar
  13. 13.
    Contreras, G., Pardo, V., Leclercq, B., et al. (2004). Sequential therapies for proliferative lupus nephritis. The New England Journal of Medicine, 350(10), 971–980.CrossRefGoogle Scholar
  14. 14.
    Kidney disease: Improving global outcomes (KDIGO) glomerulonephritis work group. (2012). KDIGO clinical practice guideline for glomerulonephritis. Kidney international Supplement, 2, 139–274.  https://doi.org/10.1038/kisup.2012.9.CrossRefGoogle Scholar
  15. 15.
    Шилов Е.М., Смирнов А.В., Козловская Н.Л. (2016). Нефрология. Клинические рекомендации. М.: ГЭОТАР-Медиа; 816с. [Shilov E.M., Smirnov A.V., Kozlovskaya N.L. Nefrologiya. Klinicheskie rekomendatsii. (Nephrology. Clinical guideline.) Moscow.: GEOTAR-Media. 2016; 816p. (In Russ.)].Google Scholar
  16. 16.
    Maschio, G., Cagnoli, L., Claroni, F., et al. (1994). ACE inhibition reduces proteinuria in normotensive patients with IgA nephropathy: a multicentre, randomized, placebo-controlled study. Nephrology, Dialysis, Transplantation, 9(3), 265–269.Google Scholar
  17. 17.
    Jo, Y. I., Na, H. Y., Moon, J. Y., et al. (2016). Effect of low-dose valsartan on proteinuria in normotensive immunoglobulin A nephropathy with minimal proteinuria: a randomized trial. The Korean Journal of Internal Medicine, 31(2), 335–343.  https://doi.org/10.3904/kjim.2014.266.CrossRefGoogle Scholar
  18. 18.
    Wand, B. F., & Roberts, I. S. (2002). Controlled prospective trial of prednisolone and cytotoxics in progressive IgA nephropathy. Journal of the American Society of Nephrology, 13, 142–148.Google Scholar
  19. 19.
    Sugawara, K., Takeda, K., Nakai, K., et al. (2008). Clinical evaluation of tonsillectomy with modified high-dose intravenous methylprednisolone therapy in patients with IgA nephropathy. Nihon Jinzo Gakkai Shi., 50(8), 1017–1023.Google Scholar
  20. 20.
    Barratt, J., & Feehally, J. (2006). Treatment of IgA nephropathy. Kidney International, 69(11), 1934–1938.  https://doi.org/10.1038/sj.ki.5000419.CrossRefGoogle Scholar
  21. 21.
    Manno, C., Torres, D. D., Rossini, M., et al. (2009). Randomized controlled clinical trial of corticosteroids plus ACE inhibitors with long-term follow-up in proteinuric IgA nephropathy. Nephrology, Dialysis, Transplantation, 24(12), 3694–3701.  https://doi.org/10.1093/ndt/gfp356.CrossRefGoogle Scholar
  22. 22.
    Tesar, V., Troyanov, S., Bellur, S., et al. (2015). Corticosteroids in IgA nephropathy: A retrospective analysis from the VALIGA study. Journal of the American Society of Nephrology, 26(9), 2248–2258.  https://doi.org/10.1681/ASN.2014070697.CrossRefGoogle Scholar
  23. 23.
    Pozzi, C., Andrulli, S., Pani, A., et al. (2010). Addition of azathioprine to corticosteroids does not benefit patients with IgA nephropathy. Journal of the American Society of Nephrology, 21(10), 1783–1790.  https://doi.org/10.1681/ASN.2010010117.CrossRefGoogle Scholar
  24. 24.
    Rauen, T., Eitner, F., Fitzner, C., et al. (2015). Intensive supportive care plus immunosuppression in IgA nephropathy. The New England Journal of Medicine, 373(23), 2225–2236.  https://doi.org/10.1056/NEJMoa1415463.CrossRefGoogle Scholar
  25. 25.
    Rasche, F. M., Keller, F., von Muller, L., et al. (2007). Sequential immunosuppressive therapy in progressive IgA nephropathy. Contributions to Nephrology, 157, 109–113.  https://doi.org/10.1159/0000102313. CrossRefGoogle Scholar
  26. 26.
    Rasche, F. M., Keller, F., Rasche, W. G., et al. (2016). Sequential therapy with cyclophosphamide and mycophenolic acid in patients with progressive IgA nephropathy: a long-term follow-up. Clinical and Experimental Immunology, 183(2), 307–316.  https://doi.org/10.1111/cei.12719.CrossRefGoogle Scholar
  27. 27.
    Austin, H. A., 3rd, Klippel, J. H., Balow, J. E., et al. (1986). Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. The New England Journal of Medicine, 314(10), 614–619.  https://doi.org/10.1056/NEJM198603063141004. CrossRefGoogle Scholar
  28. 28.
    Oshima, S., & Kawamura, O. (2008). Long-term follow-up of patients with IgA nephropathy treated with prednisolone and cyclophosphamide therapy. Clinical and Experimental Nephrology, 12(4), 264–269.  https://doi.org/10.1007/s10157-008-0045-6.CrossRefGoogle Scholar
  29. 29.
    Pozzi, C., Del Vecchio, L., & Locatelli, F. (2002). Immunosuppressive therapy in IgA glomerulonephritis with chronic renal failure: case study presentation and literature review. Giornale Italiano di Nefrologia, 19(5), 523–528.Google Scholar
  30. 30.
    Haubitz, M., Schellong, S., Gobel, U., et al. (1998). Intravenous pulse administration of cyclophosphamide versus daily oral treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitis and renal involvement: a prospective, randomized study. Arthritis and Rheumatism, 41(10), 1835–1844.  https://doi.org/10.1002/1529-0131(199810)41:10<1835::AID-ART16>3.0.CO;2-Q.CrossRefGoogle Scholar
  31. 31.
    Liu, X. W., Li, D. M., Xu, G. S., et al. (2010). Comparison of the therapeutic effects of leflunomide and mycophenolate mofetil in the treatment of immunoglobulin A nephropathy manifesting with nephrotic syndrome. International Journal of Clinical Pharmacology and Therapeutics, 48, 509–513.  https://doi.org/10.5414/CPP48509.CrossRefGoogle Scholar
  32. 32.
    Yaginuma, T., Yamamoto, H., & Mitome, J. (2011). Successful treatment of nephrotic syndrome caused by recurrent IgA nephropathy with chronic active antibody-mediated rejection three years after kidney transplantation. Clinical Transplantation, 25(23), 28–33.  https://doi.org/10.1111/j.1399-0012.2011.01456.x.CrossRefGoogle Scholar
  33. 33.
    Haas, M. (1997). Histologic subclassification of IgA nephropathy: A clinicopathologic study of 244 cases. American Journal of Kidney Diseases, 29(6), 829–842.CrossRefGoogle Scholar
  34. 34.
    Schiele, J., Nowack, R., Julian, B. A., et al. (1999). Treatment of immunoglobulin A nephropathy. Annales de Mèdecine Interne (Paris), 150(2), 127–136.Google Scholar
  35. 35.
    Walker, R. G., Yu, S. H., Owen, J. E., et al. (1990). The treatment of mesangial IgA nephropathy with cyclophosphamide, dipyridamole and warfarin: a two-year prospective trial. Clinical Nephrology, 34(3), 103–107.Google Scholar
  36. 36.
    Woo, K. T., Lee, G. S., Lau, Y. K., et al. (1991). Effects of triple therapy in IgA nephritis: a follow-up study 5 years later. Clinical Nephrology, 36(2), 60–66.Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of General PracticeKazan State Medical UniversityKazanRussia
  2. 2.OpenLab “Gene and Cell Technologies,” Institute of Fundamental Medicine and BiologyKazan Federal UniversityKazanRussia

Personalised recommendations